Jiayi Liang

Ms. Jiayi Liang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in Medicine
Verified
Journal Article
Open access
KZKa Zhang
Ka Zhang
HCHong Cao
Hong Cao
JLJiayi Liang
Jiayi Liang
XSXin Shu
Xin Shu
HSHaixia Sun
Haixia Sun
QXQihuan Xu
Qihuan Xu
The aims of this study were to compare the efficacy and safety of the addition of adefovir dipivoxil (ADV) (started at different time points) to pegylated interferon alpha-2a (PEG-INF-α2a) and PEG-INF-α2a monotherapy. This prospective, randomized study sought to evaluate the safety and efficacy of the combination of PEG-INF-α2a and ADV at different time points.120 patients were randomized into groups that received PEG-INF-α2a as monotherapy (group A) or in combination with ADV started at week 0 (group B), 12 (group C), or 24 (group D). All patients were followed for 48 weeks. Efficacy and safety analyses were performed. Patients in group a received 135 μg of PEG-INF-α2a by subcutaneous injection once weekly for 48 weeks. Patients in the ADV add-on group received 135 μg of PEG-INF-α2a subcutaneously once weekly and received 10 mg of ADV administered once daily for 48 weeks. HBV DNA, HBsAg, HBeAg, and hepatitis B e antibody levels were determined. Responses were determined at week 12 (ADV add-on), the end of treatment for PEG-INF-α2a (48weeks) and ADV (EOT) and at the end of 96 weeks of follow-up (EOF). The rate of HBV DNA loss were higher in the combination groups than group A at the week 12, week 48, the EOT and EOF (P < 0.05). The rates of HBeAg seroconversion and HBsAg loss were similar among the treatment groups (P>0.05). The alanineaminotransferase (ALT) normalization rate was higher in the combination group than group A only at the EOT (P = 0.007). By the EOF, the patients with ADV added at week 12 achieved higher rates of HBV DNA loss (71.9%), HBeAg seroconversion (50.0%), HBsAg loss (15.6%), and ALT normalization (78.1%). PEG-INF-α2a plus ADV combination therapy is safe and superior to PEG-INF-α2amonotherapyfor decreasing serum HBV DNA and normalizing the ALT level but has no significant impact on the rate of HBeAg seroconversion and HBsAg loss. Adding ADV at week 12 may be an optimal combination strategy.

19 November 2025 in Pharmacogenetics and Genomics
Verified
Journal Article
Open access
JLJiayi Liang
Jiayi Liang
LBLianne Brand
Lianne Brand
RRRikje Ruiter
Rikje Ruiter
PSPieter W. Smit
Pieter W. Smit
CVCornelis Niels F. Vos
Cornelis Niels F. Vos
TBTessa M. Bosch
Tessa M. Bosch
Background: Pharmacogenetic testing plays a key role in personalized pharmacotherapy and improving treatment outcomes; however, its benefit in clinical hyperpolypharmacy (≥ 10 chronic drugs) remains uncertain. Objective: This study assessed the impact of extensive pharmacogenetic testing in hyperpolypharmacy patients. The primary outcome was the number of actionable drug–gene interactions (DGIs) per patient; secondary outcomes included clinical recommendations, clinician adherence, and DGIs with potential for severe adverse events. Design: This intervention included 100 hyperpolypharmacy inpatients (≥ 10 drugs) from Maasstad Hospital internal ward and Antes psychiatry ward. Eligible patients (≥ 18 years) underwent a 14-gene pharmacogenetic panel test. A multidisciplinary team reviewed drug–gene interactions (DGIs), evaluated medical records, and implemented monitoring or medication adjustments as needed. Results: An average of 4.7 (interquartile range: 4.0–5.5) actionable variants in the tested pharmacogenes per patient was identified, resulting in at least one DGI in 46% of the patients, with an average of 0.6 DGI per patient. After evaluation by the multidisciplinary team, 12 out of 64 DGIs (19%) led to recommendations for interventions, with an adherence rate of 67%. In 5% of patients, the identified DGI could potentially be associated with a higher risk of hospitalization or mortality. Conclusion: Systematic pharmacogenetic panel testing in clinical hyperpolypharmacy patients identified at least one DGI in 46% of the patients. Of these DGIs, 19% led to a recommendation for intervention. This study demonstrates that pharmacogenetic panel testing holds the potential to optimize pharmacotherapy in clinical hyperpolypharmacy patients.

20 May 2025 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
JLJiayi Liang
Jiayi Liang
BWBrenda C. M. de Winter
Brenda C. M. de Winter
RHRebecca A. Hermans
Rebecca A. Hermans
SKSanne M. Kloosterboer
Sanne M. Kloosterboer
SKSusanne Kuckuck
Susanne Kuckuck
BDBram Dierckx
Bram Dierckx
Weight gain and metabolic disruptions are common in children and adolescents treated with antipsychotics, but the underlying mechanisms are unclear, complicating prevention and treatment. This study examines the impact of risperidone on appetite‐regulating hormones (insulin, leptin and bioleptin) and their relationship to body weight changes over time. In a post hoc analysis, we evaluated the correlation of appetite‐regulating hormones with BMI z‐scores during treatment and at a 6‐month follow‐up. The sample consisted of 10 participants (80% male, median age 9.7 years). A significant increase in bioleptin ( p < .05) and BMI z‐scores was observed over the 6 month period. At baseline, HOMA‐IR, insulin, leptin, and bioleptin were significantly correlated with the BMI z‐score; however, these associations were no longer observed after 6 months of treatment. Additionally, higher risperidone exposure correlated with lower appetite‐regulating hormone levels at the 6‐month mark. These findings indicate that risperidone significantly affects appetite‐regulating hormones in children and adolescents, potentially contributing to antipsychotic‐induced weight gain.

15 September 2026 in BMJ Open
Verified
Journal Article
Open access
PDF file
JLJiayi Liang
Jiayi Liang
BDBram Dierckx
Bram Dierckx
GDGwen C Dieleman
Gwen C Dieleman
TBTessa M Bosch
Tessa M Bosch
BKBirgit C P Koch
Birgit C P Koch
BWBrenda C M De Winter
Brenda C M De Winter
Introduction: Anorexia nervosa (AN) is a debilitating eating disorder with one of the highest mortality rates of all psychiatric disorders. The lifetime prevalence rates of AN might be up to 4% among females and 0.3% among males. According to a systematic review, the pooled incidence rate of AN in females is 8.8 per 100 000 person-years; 95% CI 7.8 to 9.8. The path towards full recovery is often long and only half of the patients recover completely after 10 years. As part of the treatment of AN, olanzapine is frequently used to reduce severe anxiety, agitation and obsessive compulsions. Due to a dearth of pharmacokinetic studies on olanzapine in this population with altered body composition, and side effects, doctors often dose low out of precaution. These low doses are potentially subtherapeutic and elongate the progression and the treatment. In this study, we aim to research the pharmacokinetics of olanzapine in AN patients to facilitate more adequate dosing strategies in this vulnerable group. Methods and analysis: Towards precision dosing of olanzapine in anorexia nervosa patient s (TORPEDO) is a multicentre, cross-sectional observational study. It includes patients aged 12–30 years who are being treated with olanzapine for either AN (n=30) or other non-AN psychiatric indications (n=30). The aim is to develop population pharmacokinetic models of patients with AN and those without, in order to compare how AN affects the pharmacokinetics of olanzapine. Olanzapine plasma day-curve will be obtained using capillary micro sampling. In a secondary analysis, we will examine associations between olanzapine pharmacokinetic parameters and clinical outcomes, including treatment effectiveness, extrapyramidal side effects, cardiac abnormalities and metabolic laboratory markers. Ethics and dissemination: This study was approved by the Medical Ethics Committee of the Erasmus Medical Center in Rotterdam, the Netherlands (registration number MEC-2022-0687). This ethical approval covers all study sites. Every significant amendment to the protocol will have to be approved by the medical ethics committee. The local feasibility was tested by the medical ethics committee and board of directors of all study sites included in the study. Written informed consent will be obtained from the patients and/or the legal representative(s) before enrolment in the study. Findings will be disseminated through publication in peer-reviewed journals and presentation at national and international conferences. Results will contribute to the evidence base for optimising olanzapine dosing in patients with AN.

5 October 2024
Verified
Preprint
Open access
JLJiayi Liang
Jiayi Liang
BWBrenda Winter
Brenda Winter
RHRebecca Hermans
Rebecca Hermans
SKSanne Maartje Kloosterboer
Sanne Maartje Kloosterboer
SKSusanne Kuckuck
Susanne Kuckuck
BKBirgit C. P. Koch
Birgit C. P. Koch
Weight gain and metabolic disruptions are common in children and adolescents treated with antipsychotics, but the underlying mechanisms are unclear, complicating prevention and treatment. This study examines the impact of risperidone on appetite-regulating hormones (insulin, leptin, bioleptin) and their relationship to body weight changes over time. In a post-hoc analysis, we evaluated the correlation of appetite-regulating hormones with BMI z-scores during treatment and at a 6-month follow-up. The sample consisted of 10 participants (80% male, median age 9.7 years). A significant increase in bioleptin (p < 0.05) and BMI z-scores was observed over the 6 months. Initially, HOMA-IR, insulin, leptin, and bioleptin were significantly associated with BMI z-scores, but this association diminished after 6 months of treatment. Additionally, higher risperidone exposure correlated with lower appetite-regulating hormones at the 6-month mark. These findings indicate that risperidone significantly affects appetite-regulating hormones in children and adolescents, potentially contributing to antipsychotic-induced weight gain.

15 December 2025 in Therapeutic Drug Monitoring
Verified
Journal Article
Open access
LRLisa T. Ringeling
Lisa T. Ringeling
JLJiayi Liang
Jiayi Liang
HCHilal Cetin
Hilal Cetin
SBSoma Bahmany
Soma Bahmany
RHRebecca A. Hermans
Rebecca A. Hermans
BWBrenda C.M. de Winter
Brenda C.M. de Winter
Background: Dried blood spot (DBS) sampling offers several advantages for therapeutic drug monitoring, including minimal invasiveness, low blood volume requirements, and potential for home sampling. However, obtaining spots of sufficient quality for reliable analysis remains a key challenge of DBS. This study aimed to evaluate the impact of enhanced visual and textual guidance on the quality of DBS by analyzing data from a prospective multicenter study involving children and adolescents. Methods: In total, 108 DBS cards from 56 children were assessed for spot quality. Rejection criteria included spot diameter <6 mm, smeared or irregularly shaped spots, and overlapping spots. Approval and rejection rates, overall success rates of DBS cards, and the most common rejection reasons were compared between the groups that did and did not receive the enhanced visual and textual support (intervention). Results: Pre-intervention : 47.6% of the DBS cards contained at least 1 spot qualitatively acceptable for analysis, and 25.7% of all spots qualified for analysis. Post-intervention : the acceptance rates increased to 86.6% and 64.3%, respectively. In both the pre- and post-intervention groups , the most common reason for rejection was the presence of smeared or irregularly shaped spots. Conclusions: Continued improvements in DBS quality rely on effectively addressing challenges associated with home sampling challenges, which is critical for the seamless incorporation of DBS into clinical practice.